Boston Scientific
RELATED CONTENT
November 14, 2023 — Boston Imaging, the United States headquarters of Samsung’s digital radiography and ultrasound busin ...
November 14, 2023 
February 28, 2022 — NeuroLogica Corp., the U.S. healthcare subsidiary of Samsung, announced today that the company’s Dig ...
February 28, 2022 
March 25, 2021 — Boston Scientific Corporation announced positive data from the TARGET study of the TheraSphere Y-90 ...
March 25, 2021 
March 18, 2021 — The U.S. Food and Drug Administration (FDA) has cleared Boston Scientific's TheraSphere Y-90 Glass ...
March 18, 2021 
December 23, 2019 — The U.S. Food and Drug Administration cleared for marketing in the U.S. the first fully disposable d ...
December 23, 2019 
Boston Scientific Corp. announced the completion of its acquisition of BTG plc. pursuant to the previously announced scheme of arrangement. BTG develops and commercializes products used in minimally invasive procedures targeting cancer and vascular diseases, as well as specialty pharmaceuticals.
August 20, 2019 
Varian announced it has signed an asset purchase agreement to acquire the Boston Scientific portfolio of drug-loadable microsphere and bland embolic bead products for treating arteriovenous malformations and hypervascular tumors. When completed, this acquisition, in combination with the recent acquisitions of Endocare and Alicon, will expand Varian's portfolio of multidisciplinary integrated cancer care solutions.
July 03, 2019 
Boston Scientific Corp. announced the close of its acquisition of Augmenix Inc., developer of the SpaceOAR Hydrogel System to help reduce common and debilitating side effects that men may experience after receiving radiotherapy to treat prostate cancer. The biodegradable SpaceOAR hydrogel is injected between the rectum and prostate to decrease a patient's exposure to rectal radiation and thereby reduce rectal radiation injury – one of the most common complications of prostate radiotherapy.
October 17, 2018 
Boston Scientific has entered into a definitive agreement to acquire Augmenix Inc., a privately-held company which has developed and commercialized the SpaceOAR System to reduce common and debilitating side effects that men may experience after receiving prostate cancer radiotherapy. The transaction consists of an upfront cash payment of $500 million, and up to $100 million for reaching sales-based milestones.
September 07, 2018